WHO Drug Information Vol. 17, No. 2, 2003
(2003; 64 pages)

Table des matières

	Good Manufacturing Practices
		Implementation of good manufacturing practices
	Personal Perspectives
		Pharmacogenetics and existing therapies
	Safety Issues
		Fluticasone and adrenal crisis
		Thiazolidinediones experience
		Cefepime, ceftazidime and neurotoxicity
		Interstitial nephritis and proton pump inhibitors
		Interactions with grapefruit juice
	Current Topics
		New network for guideline development
		Fake artesunate tablets circulating again
		European Union enlargement: observers to EMEA
		Clinical cancer research review
		New foundation will develop tests for infectious diseases
		TDR research training in 2004
		Managing drug supply for primary health care
		Latin American pharmacotherapy course
	Regulatory and Safety Action
		Gefitinib approved for lung cancer
		New breath test for monitoring asthma
		Risperidone: prescribing information update
		Pan Pharmaceuticals product recalls
		Telithromycine and myasthenia gravis
		Astemizole: marketing suspension
		Somatropin: negative opinion
		Repaglinide and gemfibrozil: hazardous interaction
		Adhesion prevention solution global withdrawal
		Counterfeit Lipitor®
		Paroxetine: avoid in children and adolescents
		Aprepitant for nausea and vomiting during chemotherapy
		Agalsidase beta approved
		Imatinib mesylate approved for paediatric leukaemia
		Drug-eluting stent for clogged heart arteries
		Pegvisomant for acromegaly
	Aspects of Quality Assurance
		Fixed-combination medicines: an Australian perspective
	Recent Publications and Sources of Information
		International Travel & Health
		Affordability of medicines
		Drugs and money
		ABPI launches online clinical trials register
		Expert Committee on Drug Dependence Report
		Biomedical research in human subjects
	International Nonproprietary Names for Pharmaceutical Substances (INN)

WHO Drug Information Vol. 17, No. 2, 2003

WHO Drug Information is now available at:
http://www.who.int/druginformation